Shanghai Fosun Pharmaceutical (600613.SH) released its first quarter performance, with a net profit attributable to shareholders of 14.99 million yuan, a decrease of 37.38% year-on-year.

China Fortune Financial News APP learned that Shenqi Pharmaceutical (600613.SH) disclosed its first quarter report for 2025. During the reporting period, the company achieved a revenue of 480 million yuan, a year-on-year decrease of 16.47%; the net profit attributable to the parent company was 14.99 million yuan, a year-on-year decrease of 37.38%; the non-net profit was 14.99 million yuan, a year-on-year decrease of 36.94%. The basic earnings per share were 0.03 yuan.